🚀 VC round data is live in beta, check it out!
Fleury Valuation Multiples
Discover revenue and EBITDA valuation multiples for Fleury and similar public comparables like SonoScape, Vimian Group, Diagnostyka, Neogen and more.
Fleury Overview
About Fleury
Fleury SA is engaged in the provision of medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics and ophthalmology areas and offers its digital healthcare platform. The company carries out its activities through customer service units and hospital-based units. Furthermore, the company has a mobile service operation with coverage in municipalities in addition to a digital platform. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from Diagnostic Medicine Segment.
Founded
1926
HQ
Employees
22.9K
Website
Financials (LTM)
EV
$2B
Fleury Financials
Fleury reported last 12-month revenue of $2B and EBITDA of $422M.
In the same LTM period, Fleury generated $441M in gross profit, $422M in EBITDA, and $123M in net income.
Revenue (LTM)
Fleury P&L
In the most recent fiscal year, Fleury reported revenue of $2B and EBITDA of $478M.
Fleury expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $441M | XXX | $443M | XXX | XXX | XXX |
| Gross Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBITDA | $422M | XXX | $478M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $123M | XXX | $123M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | — | — | $805M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Fleury Stock Performance
Fleury has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Fleury's stock price is $3.43.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $0.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialFleury Valuation Multiples
Fleury trades at 1.5x EV/Revenue multiple, and 5.9x EV/EBITDA.
EV / Revenue (LTM)
Fleury Financial Valuation Multiples
As of April 19, 2026, Fleury has market cap of $2B and EV of $2B.
Equity research analysts estimate Fleury's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fleury has a P/E ratio of 15.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 5.9x | XXX | 5.2x | XXX | XXX | XXX |
| EV/EBIT | 10.2x | XXX | 10.0x | XXX | XXX | XXX |
| EV/Gross Profit | 5.6x | XXX | 5.6x | XXX | XXX | XXX |
| P/E | 15.1x | XXX | 15.1x | XXX | XXX | XXX |
| EV/FCF | 18.6x | XXX | 7.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Fleury Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Fleury Margins & Growth Rates
Fleury's revenue in the last 12 month grew by 13%.
Fleury's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Fleury's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fleury's rule of X is 48% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Fleury Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | (3%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 48% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Fleury Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Fleury | XXX | XXX | XXX | XXX | XXX | XXX |
| SonoScape | XXX | XXX | XXX | XXX | XXX | XXX |
| Vimian Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Diagnostyka | XXX | XXX | XXX | XXX | XXX | XXX |
| Neogen | XXX | XXX | XXX | XXX | XXX | XXX |
| GRAIL | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fleury M&A Activity
Fleury acquired XXX companies to date.
Last acquisition by Fleury was on XXXXXXXX, XXXXX. Fleury acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Fleury
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialFleury Investment Activity
Fleury invested in XXX companies to date.
Fleury made its latest investment on XXXXXXXX, XXXXX. Fleury invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Fleury
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Fleury
| When was Fleury founded? | Fleury was founded in 1926. |
| Where is Fleury headquartered? | Fleury is headquartered in Brazil. |
| How many employees does Fleury have? | As of today, Fleury has over 22K employees. |
| Is Fleury publicly listed? | Yes, Fleury is a public company listed on B3. |
| What is the stock symbol of Fleury? | Fleury trades under FLRY3 ticker. |
| When did Fleury go public? | Fleury went public in 2009. |
| Who are competitors of Fleury? | Fleury main competitors are SonoScape, Vimian Group, Diagnostyka, Neogen. |
| What is the current market cap of Fleury? | Fleury's current market cap is $2B. |
| What is the current revenue of Fleury? | Fleury's last 12 months revenue is $2B. |
| What is the current revenue growth of Fleury? | Fleury revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Fleury? | Current revenue multiple of Fleury is 1.5x. |
| Is Fleury profitable? | Yes, Fleury is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fleury? | Fleury's last 12 months EBITDA is $422M. |
| What is Fleury's EBITDA margin? | Fleury's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Fleury? | Current EBITDA multiple of Fleury is 5.9x. |
| What is the current FCF of Fleury? | Fleury's last 12 months FCF is $134M. |
| What is Fleury's FCF margin? | Fleury's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Fleury? | Current FCF multiple of Fleury is 18.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.